Dysgerminoma with Estrogen-Producing Functioning Stroma Presenting Precocious Puberty

Shunsuke Nagase, Kanako Ogura, Karin Ashizawa, Nana Nakazawa-Tanaka, Masahiko Urao, Masaharu Fukunaga, Yuto Yamazaki, Hironobu Sasano, and Toshiharu Matsumoto

1Department of Diagnostic Pathology, Juntendo University Nerima Hospital, Tokyo, Japan
2Department of Pediatric Surgery, Juntendo University Nerima Hospital, Tokyo, Japan
3Department of Pathology, Shin-Yurigaoka General Hospital, Kawasaki, Japan
4Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan

Correspondence should be addressed to Shunsuke Nagase; s-nagase@juntendo.ac.jp

Received 8 January 2021; Accepted 16 April 2021; Published 22 April 2021

Academic Editor: Janina Kulka

Copyright © 2021 Shunsuke Nagase et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dysgerminoma is a malignant ovarian germ cell tumor, and unlike sex-cord stromal tumors, endocrine manifestation is considered rare. To date, three cases of dysgerminoma with estrogenic manifestation have been reported all of which presented an unusual morphology that contained a human chorionic gonadotropin- (hCG-) secreting syncytiotrophoblast [2–4]. It has been postulated that hCG transformed nonneoplastic ovarian stroma, the so-called functioning stroma, and produced estrogen. However, endocrine manifestation in a conventional dysgerminoma that lacks a syncytiotrophoblast has never been reported. Here, we report the first case of dysgerminoma with hyperestrogenism that showed a conventional morphology.

1. Introduction

Dysgerminoma is a malignant ovarian germ cell tumor, and unlike sex cord-stromal tumors, endocrine manifestation is considered rare [1]. To date, three cases of dysgerminoma with estrogenic manifestation have been reported all of which presented an unusual morphology that contained a human chorionic gonadotropin- (hCG-) secreting syncytiotrophoblast [2–4]. It has been postulated that hCG transformed nonneoplastic ovarian stroma, the so-called functioning stroma, and produced estrogen. However, endocrine manifestation in a conventional dysgerminoma that lacks a syncytiotrophoblast has never been reported. Here, we report the first case of dysgerminoma with hyperestrogenism that showed a conventional morphology.

2. Case Presentation

A 7-year-old girl presented with a breast development with four-month duration, vaginal discharge, and rapid height increase. Her past medical history and family history were unremarkable. She was 130 cm in height (+2.24 standard deviation) and 28.9 kg in weight (+1.62 standard deviation). Physical examination revealed a breast development in
Hydroxysteroid dehydrogenase (17,20-lyase), 3β-hydroxysteroid dehydrogenase type 2 and 5, 3β-hydroxysteroid dehydrogenase type 1, and steroid sulfatase but negative for 17β-HSD types 2 and 5, 5α-reductases 1 and 2, and estrone sulfotransferase. These results indicated that the stromal cells were enzymatically active and produced E2 independently.

The postoperative course was uneventful, and the patient was discharged three days after the surgery. Serum E2 level declined below the detection limit; LH and FSH returned within the normal range. The serum β-hCG level was constantly low throughout the observation (Table 1). The patient underwent three courses of postoperative chemotherapy, and no sign of recurrence has been observed for at least two years.

### 3. Discussion

We reported a case of dysgerminoma with estrogen-producing functioning stroma. Although three similar cases have been reported to date, the mechanism of estrogen biosynthesis in our case was distinct from the previous cases [2–4]. Functioning stroma is a nonneoplastic ovarian stroma that produces various sex steroids. It is commonly observed in mucinous cystadenomas and Krukenberg tumors, but it can arise in any type of ovarian tumor [5, 6]. The development of functioning stroma remains unclear; however, since it is frequently observed in pregnant women, hCG is regarded as one of the triggers [5, 6]. All previous cases of dysgerminoma with hyperestrogenism presented elevated serum hCG levels and histology of a special subtype that contains abundant syncytiotrophoblast. Thus, it has been postulated that the syncytiotrophoblast produced hCG, as in normal placenta, and induced functioning stroma [5, 7]. On the contrary, our case lacked syncytiotrophoblast, and the serum hCG level was constantly low throughout the observation. However, we discovered that the stromal cells expressed various steroidogenic enzymes involved in estrogen biosynthesis and produced estrogen independently.

Among these enzymes, P450arom is the most important factor as it catalyzes the final step of estrogen biosynthesis. Nevertheless, since it is widely distributed in the peripheral tissue, determining how much the functioning stroma contributes to aromatization is difficult. Previous studies reported that 9 to 80% of the ovarian tumors with functioning stroma expressed P450arom; however, the authors conceived that most aromatization may have occurred in the peripheral tissue rather than the ovary as the expression of P450arom was focal [5, 8]. In our case, the stromal cells were diffusely positive for P450arom, suggesting that most stroma-derived androgen were aromatized by the stromal cells in an autocrine manner.

Our case demonstrates that even a conventional dysgerminoma can produce estrogen through functioning stroma. Since most dysgerminomas occur during the reproductive age where endogenous estrogen can mask hyperestrogenism [1, 6], many estrogen-producing dysgerminomas may have been overlooked. This presumption is also supported by the fact that endocrine manifestation has only been reported in prepubertal patients. Although serum hormone levels are not measured routinely in ovarian tumors, immunohistochemistry for the steroidogenic enzymes, especially P450arom, could be utilized in the future study to reveal subclinical endocrine manifestation in dysgerminoma.

### Table 1: Changes of serum hormone levels before (pre-op) and after (post-op) operation.

|                | Pre-op | Post-op (POD 0) | Post-op (POD 8) |
|----------------|--------|-----------------|-----------------|
| E2 (pg/mL)     | 41.7   | 8.8             | b.d.l.          |
| LH (mIU/mL)    | b.d.l. | b.d.l.          | 0.9             |
| FSH (mIU/mL)   | b.d.l. | b.d.l.          | 3.6             |
| β-hCG (ng/mL)  | 0.2    | 0.2             | 0.2             |

b.d.l.: below the detection limit; E2: estradiol; FSH: follicle-stimulating hormone; LH: luteinizing hormone; POD: postoperative days; β-hCG: human chorionic gonadotropin beta subunit.
Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

References

[1] C. P. Crum, M. R. Nucci, B. E. Howitt et al., *Diagnostic Gynecologic and Obstetric Pathology*, Elsevier, Philadelphia, 3rd edition, 2018.

[2] A. M. Hain, “An unusual case of precocious puberty associated with ovarian dysgerminoma,” *The Journal of Clinical Endocrinology*, vol. 9, no. 12, pp. 1349–1358, 1949.

[3] E.-S. Song, J.-P. Lee, J.-H. Han et al., “Dysgerminoma of the ovary with precocious puberty: a case report,” *Gynecological Endocrinology*, vol. 23, no. 1, pp. 34–37, 2007.

[4] G. Ueda, N. Hamanaka, K. Hayakawa et al., “Clinical, histochemical, and biochemical studies of an ovarian dysgerminoma with trophoblasts and Leydig cells,” *American journal of obstetrics and gynecology*, vol. 114, no. 6, pp. 748–754, 1972.

[5] H. Ishikura and H. Sasano, “Histopathologic and immunohistochemical study of steroidogenic cells in the stroma of ovarian tumors,” *International Journal of Gynecological Pathology*, vol. 17, no. 3, pp. 261–265, 1998.

[6] R. E. Scully, R. H. Young, and P. B. Clement, “Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad...
Ligament,” in *Atlas of Tumor Pathology*, Armed Forces Institute of Pathology, Washington, D.C, 1998.

[7] X. Matias-Guiu and J. Prat, “Ovarian tumors with functioning stroma an immunohistochemical study of 100 cases with human chorionic gonadotropin monoclonal and polyclonal antibodies,” *Cancer*, vol. 65, no. 9, pp. 2001–2005, 1990.

[8] N. Kato, T. Hayasaka, J. Takeda, M. Osakabe, and H. Kurachi, “Ovarian tumors with functioning stroma,” *International Journal of Gynecological Pathology*, vol. 32, no. 6, pp. 556–561, 2013.